-transparent.png){kind=logo}
12-Hydroxyeicosatetraenoic acid (12-HETE) is assumed to play an important role in the pathogenesis of inflammatory skin diseases. Recently, high-affinity binding sites for this eicosanoid have been identified on human keratinocytes by our group. Since ciclosporin exerts therapeutic effects in chronic inflammatory dermatoses such as psoriasis or atopic eczema, the influence of the drug on 12(S)-HETE binding to human keratinocytes was studied. No competitive inhibition of 12(S)-HETE binding was observed in ciclosporin concentrations between 10(-10) and 10(-6) M. In contrast, pretreatment of epidermal cells for 24 h resulted in a dose-dependent decrease of specific 12(S)-HETE binding. The analysis of saturation curves showed that the inhibition of 12(S)-HETE binding by ciclosporin was due to the decrease of 12-HETE binding sites, while receptor affinity remained unchanged. In addition, ciclosporin blocked the interferon-gamma-induced increase in epidermal 12(S)-HETE binding. These findings suggest that the effects of ciclosporin in cutaneous disorders could be partly mediated via an influence on epidermal 12(S)-HETE binding.
P Arenberger, and
T Ruzicka, and
L Kemény
January 1999,
Life sciences,
P Arenberger, and
T Ruzicka, and
L Kemény
March 1991,
Agents and actions,
P Arenberger, and
T Ruzicka, and
L Kemény
April 1990,
The Journal of investigative dermatology,
P Arenberger, and
T Ruzicka, and
L Kemény
January 1997,
Free radical biology & medicine,
P Arenberger, and
T Ruzicka, and
L Kemény
November 1996,
Biochemical and biophysical research communications,
P Arenberger, and
T Ruzicka, and
L Kemény
January 1991,
Archives of dermatological research,
P Arenberger, and
T Ruzicka, and
L Kemény
May 1995,
Biological & pharmaceutical bulletin,
P Arenberger, and
T Ruzicka, and
L Kemény
January 1993,
Acta physiologica Scandinavica,
P Arenberger, and
T Ruzicka, and
L Kemény
May 1992,
Experimental eye research,
P Arenberger, and
T Ruzicka, and
L Kemény
December 1989,
Journal of lipid research,
